Aurobindo Pharma Share Price Gains Nearly 3%: Here’s Why the Stock is in Focus Today

Aurobindo Pharma share price rose nearly 3% to ₹1,222.9 on the BSE after its subsidiary, Eugia Pharma Specialities, received final approval from the US FDA to manufacture and sell Dasatinib tablets in the US. By 12:22 PM, the stock was trading 2.65% higher at ₹1,219.6, while the Sensex was up 0.20%.

What Is Dasatinib and Why It Matters

Dasatinib is used to treat specific types of blood cancers like chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) in adults, especially in patients resistant or intolerant to earlier treatments like imatinib. The approval is for multiple strengths: 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg.

Read More, Bank Nifty Retreats from Highs, Drops 423 Points Amid HDFC Bank Profit-Taking on Apr 23.  

Big Market Opportunity

The approved product is bioequivalent to Sprycel from Bristol-Myers Squibb. It has a large market size of $1.8 billion (as of February 2025), and Eugia plans to launch it in Q1FY26. This approval marks Eugia Pharma’s 181st ANDA approval, reinforcing its strong presence in oncology and speciality drugs.

About Aurobindo Pharma

Aurobindo Pharma is a global pharma company headquartered in Hyderabad, India. It produces a wide range of generic and branded drugs along with active pharmaceutical ingredients (APIs). Operating in over 150 countries, the company runs more than 30 manufacturing and packaging facilities. Its diverse product portfolio covers CNS, anti-retroviral, cardiovascular, antibiotics, gastrointestinal, anti-diabetics, and anti-allergy drugs, all backed by a solid R&D team.

This latest FDA approval strengthens Aurobindo Pharma’s US pipeline and reinforces its growth in the high-value oncology segment, boosting investor confidence and the stock price.

Conclusion

The USFDA approval for Dasatinib is a major win for Aurobindo Pharma, strengthening its oncology portfolio and opening doors to a multi-billion-dollar market. As the company gears up for the Q1FY26 launch, this move further solidifies its presence in the US generic drug space and boosts investor sentiment.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.              

Investments in securities market are subject to market risks, read all the related documents carefully before investing.